Read by QxMD icon Read

Vaccination in COPD

M Zysman, F Chabot, P Devillier, B Housset, C M Panzini, N Roche
The Société de Pneumologie de Langue Française proposes a decision algorithm on long-term pharmacological COPD treatment. A working group reviewed the literature published between January 2009 and May 2016. This document lays out proposals and not guidelines. It only focuses on pharmacological treatments except vaccinations, smoking cessation treatments and oxygen therapy. Any COPD diagnosis, based on pulmonary function tests, should lead to recommend smoking cessation, vaccinations, physical activity, pulmonary rehabilitation in case of activity limitation, and short-acting bronchodilators...
November 24, 2016: Revue des Maladies Respiratoires
Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Kanzo Suzuki, Masahiro Katsurada, Naoko Katsurada, Masafumi Misawa, Yoshihito Otsuka, Kyoko Kondo, Yoshio Hirota
Lung cancer is a leading cause of cancer-related death, and patients with lung cancer are a priority group for influenza vaccination. However, few studies have assessed the immunogenicity of the influenza vaccine in these patients. Here, we performed a prospective study to evaluate the immunogenicity of the influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Twenty-five patients with lung cancer undergoing anticancer chemotherapy and 26 patients with chronic obstructive pulmonary disease (COPD) as controls were enrolled...
November 7, 2016: Human Vaccines & Immunotherapeutics
Katrijn Neyt, Corine H GeurtsvanKessel, Kim Deswarte, Hamida Hammad, Bart N Lambrecht
Inducible bronchus-associated lymphoid tissue (iBALT) is a long lasting tertiary lymphoid tissue that can be induced following influenza A virus (IAV) infection. Previous studies have shown that iBALT structures containing germinal center (GC) B cells protect against repeated infection by contributing locally to the cellular and humoral immune response. If we are to exploit this in vaccination strategies, we need a better understanding on how iBALT structures are induced. One hypothesis is that the strength of the initial innate response dictates induction of iBALT...
2016: Frontiers in Immunology
Nicholas A Zwar, Jeremy M Bunker, Helen K Reddel, Sarah M Dennis, Sandy Middleton, Onno C P van Schayck, Alan J Crockett, Iqbal Hasan, Oshana Hermiz, Sanjyot Vagholkar, Wei Xuan, Guy B Marks
BACKGROUND: Early detection and intervention for chronic obstructive pulmonary disease (COPD) could potentially slow disease progress and minimize harm. OBJECTIVES: To assess the effectiveness of early intervention by a practice nurse-GP team on quality of life (QoL) and process of care in patients with newly diagnosed COPD, compared with usual care. Nurses and GPs in intervention practices were educated to develop and implement disease management plans for COPD...
August 17, 2016: Family Practice
A H de Boer, P Hagedoorn, M Hoppentocht, F Buttini, F Grasmeijer, H W Frijlink
INTRODUCTION: Early dry powder inhalers (DPIs) were designed to deliver low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied today as repair actions for the poor design choices to achieve acceptable lung deposition with these inhalers. AREAS COVERED: The consequences of the choices made for early DPI development are discussed with respect of efficacy, production costs and safety...
August 18, 2016: Expert Opinion on Drug Delivery
Benjamin Luke Duell, Yu-Ching Su, Kristian Riesbeck
Nontypeable Haemophilus influenzae (NTHi) is a commensal microbe often isolated from the upper and lower respiratory tract. This bacterial species can cause sinusitis, acute otitis media in preschool children, exacerbations in patients suffering from chronic obstructive pulmonary disease, as well as conjunctivitis and bacteremia. Since the introduction of a vaccine against H. influenzae serotype b in the 1990s, the burden of H. influenzae-related infections has been increasingly dominated by NTHi. Understanding the ability of NTHi to cause infection is currently an expanding area of study...
November 2016: FEBS Letters
Tatsuhiko Harada, Yuji Ishimatsu, Atsuko Hara, Towako Morita, Shota Nakashima, Tomoyuki Kakugawa, Noriho Sakamoto, Kosuke Kosai, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Shigeru Kohno
Secondary bacterial pneumonia (SBP) during influenza increases the severity of chronic obstructive pulmonary disease (COPD) and its associated mortality. Macrolide antibiotics, including clarithromycin (CAM), are potential treatments for a variety of chronic respiratory diseases owing to their pharmacological activities, in addition to antimicrobial action. We examined the efficacy of CAM for the treatment of SBP after influenza infection in COPD. Specifically, we evaluated the effect of CAM in elastase-induced emphysema mice that were inoculated with influenza virus (strain A/PR8/34) and subsequently infected with macrolide-resistant Streptococcus pneumoniae CAM was administered to the emphysema mice 4 days prior to influenza virus inoculation...
September 2016: Journal of Pharmacology and Experimental Therapeutics
Elizabeth Hohner, Melinda Ortmann, Umbreen Murtaza, Sheeva Chopra, Patricia A Ross, Meghan Swarthout, Leigh Efird, Emily Pherson, Mustapha Saheed
PURPOSE: The implementation of an emergency department (ED)-based clinical pharmacist transitions-of-care (TOC) program is described. SUMMARY: The intervention program consisted of collaboration between ED and ambulatory care pharmacists to provide patient-specific comprehensive medication review and education in the ED setting and to help ensure a coordinated transition to the ambulatory care setting by scheduling an ambulatory pharmacy clinic or home-based visit...
August 1, 2016: American Journal of Health-system Pharmacy: AJHP
Roger Baxter, Arnold Yee, Laurie Aukes, Vincenza Snow, Bruce Fireman, Bruce Atkinson, Nicola P Klein
PURPOSE: In the United States, the 13-valent pneumococcal conjugate vaccine is recommended in persons ⩾65years of age, and persons ⩽65years of age with immunocompromising (IC) conditions. For invasive pneumococcal disease (IPD) prevention in those ⩽65 with non-IC medical conditions, the 23-valent polysaccharide vaccine is recommended. This group is at higher risk of IPD than the general population, but the level of risk is not well-quantified. We estimated IPD risk by individual underlying medical conditions, and by total number of conditions, for persons ⩾18years of age...
August 5, 2016: Vaccine
David C Bulir, Steven Liang, Amanda Lee, Sylvia Chong, Elizabeth Simms, Christopher Stone, Charu Kaushic, Ali Ashkar, James B Mahony
Chlamydia trachomatis infections in women are often asymptomatic and if left untreated can lead to significant late sequelae including pelvic inflammatory disease and tubal factor infertility. Vaccine development efforts over the past three decades have been unproductive and there is no vaccine approved for use in humans. The existence of serologically distinct strains or serovars of C. trachomatis mandates a vaccine that will provide protection against multiple serovars. Chlamydia spp. use a highly conserved type III secretion system (T3SS) composed of both structural and effector proteins which is an essential virulence factor for infection and intracellular replication...
July 25, 2016: Vaccine
Timothy F Murphy, Charmaine Kirkham, Antoinette Johnson, Aimee L Brauer, Mary Koszelak-Rosenblum, Michael G Malkowski
Moraxella catarrhalis causes otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease (COPD). A vaccine to prevent M. catarrhalis infections would have an enormous impact globally in preventing morbidity caused by M. catarrhalis in these populations. Using a genome mining approach we have identified a sulfate binding protein, CysP, of an ATP binding cassette (ABC) transporter system as a novel candidate vaccine antigen. CysP expresses epitopes on the bacterial surface and is highly conserved among strains...
July 19, 2016: Vaccine
Takeshi Kaneko
Respiratory tract infections are important events in the pathophysiology of COPD, and are known as one of the risk factors for COPD onset. More importantly, they are the most common risk factor of COPD exacerbations. As microorganisms for the causes of infections, both virus and bacteria are representative. Since exacerbations increase the decline in lung function, deterioration in health status and risk of death in COPD, prevention of exacerbations via appropriate long-term management, including smoking cessation, influenza and pneumococcal vaccinations, and pharmacotherapy, is very important...
May 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
A D Protasov, M P Kostinov, A V Zhestkov, M L Shteiner, O O Magarshak, T A Kostinova, A A Ryzhov, D V Pakhomov, D A Blagovidov, M I Panina
AIM: To provide a rationale for choosing the optimal tactics of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease (COPD) in the context of evidence-based medicine and on the basis of immunological and clinical data. SUBJECTS AND METHODS: Patients with COPD were examined during a year after vaccination with a 13-valent pneumococcal conjugate (Prevenar-13, PCV13) and a 23-valent pneumococcal polysaccharide (Pnemo-23, PPV23) vaccines...
2016: Terapevticheskiĭ Arkhiv
T M Eagan, J A Hardie, Å Jul-Larsen, T B Grydeland, P S Bakke, R J Cox
BACKGROUND: COPD patients are advised vaccination against seasonal influenza, yet few studies have evaluated the protective antibody titers obtained in this patient group. AIMS: 1) To describe protective titers in COPD patients who self-reported influenza vaccination compared with vaccinated subjects without COPD and unvaccinated COPD patients, 2) analyze whether clinical parameters predicted influenza-specific antibody titers, and 3) whether antibody titers to influenza A at baseline could predict exacerbation risk or 5 years all-cause mortality...
June 2016: Respiratory Medicine
Farzaneh Sanei, Tom Wilkinson
Influenza infection is an important cause of global mortality and morbidity with the greatest impact on older people and those with chronic disease. Patients with chronic obstructive pulmonary disease (COPD) are particularly vulnerable to influenza, with evidence for increased incidence and severity of infection. In this patient group influenza is associated with exacerbations and pneumonia which result in a significant healthcare burden and premature mortality. Influenza vaccination and in particular the use of the seasonal trivalent influenza vaccine (TIV) is recommended for patients with COPD...
August 2016: Therapeutic Advances in Respiratory Disease
Marina Cerquetti, Maria Giufrè
Nontypeable Haemophilus influenzae (NTHi) is increasingly recognized as emerging pathogen. The routine immunization of infants with conjugated vaccines against H. influenzae type b (Hib) has greatly reduced the incidence of invasive Hib disease; however a marked change in the predominant invasive serotype from Hib to NTHi has occurred. Localized infections where the role of H. influenzae is important, such as otitis media in children and acute exacerbations in chronic obstructive pulmonary disease (COPD) in adults, are almost exclusively associated with NTHi isolates...
September 2016: Human Vaccines & Immunotherapeutics
Benjamas Chuaychoo, Uraiwan Kositanont, Nuttapol Rittayamai, Parichat Niyomthong, Thaweesak Songserm, Khun Nanta Maranetra, Kanokwan Rattanasaengloet, Arth Nana
The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination...
July 2, 2016: Human Vaccines & Immunotherapeutics
Seung-Hyun Cha, Jeong-Hun Paik, Mi-Ra Lee, Huiho Yang, Seung-Guk Park, Young-Jee Jeon, Sunmi Yoo
Influenza vaccination is an effective strategy to reduce morbidity and mortality, particularly for those who have decreased lung functions. This study was to identify the factors that affect vaccination coverage according to the results of pulmonary function tests depending on the age. In this cross-sectional study, data were obtained from 3,224 adults over the age of 40 who participated in the fifth National Health and Nutrition Examination Survey and underwent pulmonary function testing in 2012. To identify the factors that affect vaccination rate, logistic regression analysis was conducted after dividing the subjects into two groups based on the age of 65...
May 2016: Journal of Korean Medical Science
Elaine M Mokrzan, Michael O Ward, Lauren O Bakaletz
UNLABELLED: Nontypeable Haemophilus influenzae (NTHI), a commensal of the human nasopharynx (hNP), is a common cause of biofilm-associated diseases of the respiratory tract. However, NTHI biofilm biology at the average hNP temperature, i.e., 34°C, has not been well studied. Here we grew NTHI biofilms at 34°C and 37°C, to evaluate relative biofilm growth, expression, and function of the type IV pilus (Tfp), a critical adhesin important for NTHI biofilm formation. The kinetics and regulation of Tfp expression in NTHI biofilms are unclear, especially at 34°C...
October 1, 2016: Journal of Bacteriology
Fanny W Ko, Ka Pang Chan, David S Hui, John R Goddard, Janet G Shaw, David W Reid, Ian A Yang
The literature of acute exacerbation of chronic obstructive pulmonary disease (COPD) is fast expanding. This review focuses on several aspects of acute exacerbation of COPD (AECOPD) including epidemiology, diagnosis and management. COPD poses a major health and economic burden in the Asia-Pacific region, as it does worldwide. Triggering factors of AECOPD include infectious (bacteria and viruses) and environmental (air pollution and meteorological effect) factors. Disruption in the dynamic balance between the 'pathogens' (viral and bacterial) and the normal bacterial communities that constitute the lung microbiome likely contributes to the risk of exacerbations...
October 2016: Respirology: Official Journal of the Asian Pacific Society of Respirology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"